CITELINE：制药研发年度回顾白皮书2023（英文版）（52页）.pdf

1、Pharma R&D Annual Review 2023by Ian Lloyd,Senior Director,Pharmaprojects at CitelineWhite PaperApril 2023Reimagining the futureone chapter at a timeWelcome to Pharmaprojects 2023 review of trends in pharmaceutical R&D.For over 30 years now,Ive been taking an annual look at the evolution of pharma R&

2、D,and in this article,Ill examine the state of play at the start of 2023.Well assess industry trends by examining the pipeline by company,therapeutic area,disease,target,and drug type,using data from primarily Pharmaprojects,part of the Citeline suite of products,which has been tracking global drug

3、development since 1980.This report will be followed up by our annual supplement reviewing the New Active Substance launches for the year just passed.But here,well tell the story of pharma R&D as it is today:an epic tale,with a rich cast of characters and a global scope,and no doubt a number of unexp

4、ected plot twists.Hopefully,it will be a real page-turner!Regular readers of this report(which has been running since 1993,so is presented here in its 31st edition)will know that in recent years,Ive threaded a different theme through each edition,to highlight points,to draw analogies,and to add a li

5、ttle character into what could otherwise be a rather lengthy narrative through a potentially dreary parade of statistics,charts,and tables.Themes selected so far have included astronomy,movies,the natural world,music,food and drink,science fiction,and,last year,travel.This year,I decided to make a f

6、ew nods to the world of literature and books to help illustrate my points.Storytelling is as old as humanity itself,and fiction has always been used as a proxy to help us to understand the real world.The best literature enlightens,thrills,amuses,and engages the reader.Im certainly no Shakespeare,but